BioPharmSignal logoBioPharmSignal

Biotech News

Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114

Protagenic Therapeutics (PTIX)Protagenic TherapeuticsCompany update

NEW YORK, NY / ACCESS Newswire / April 23, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company pioneering first-in-class neuropeptide therapies for stress-related neuropsychiatric disorders, today announced the appointment of Bill Nichols Jr. as President. This strategic leadership addition, combined with a thoughtful optimization of the...

Related news

ADXNAddex Therapeutics2026-06-25 05:00 EST

Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

ADXNAddex Therapeutics2026-06-22 05:00 EST

Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026

AXSMAxsome2026-09-17 11:00 EST

Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026

GANXGain Therapeutics2026-09-17 11:00 EST

Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference

AXSMAxsome2026-09-02 11:00 EST

Axsome Therapeutics to Participate in Upcoming Investor Conferences

GANXGain Therapeutics2026-08-25 11:00 EST

Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference

TEVATeva Pharmaceutical Industries2026-08-19 12:30 EST

U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

CGTXCognition Therapeutics2026-08-06 20:15 EST

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

IKTInhibikase Therapeutics2026-07-23 12:00 EST

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

KTTAPasithea Therapeutics2026-07-21 11:00 EST

Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026

View all latest news

Protagenic Therapeutics

Protagenic Therapeutics is a biotechnology company focused on neuropsychiatric and stress-related disorders. Its story is built around the idea that peptide-based or related approaches can address difficult CNS conditions.

Recent company news

PTIXProtagenic Therapeutics2026-05-19 08:15 EST

Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner

PTIXProtagenic Therapeutics2026-04-23 08:15 EST

Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114

PTIXProtagenic Therapeutics2026-03-17 08:00 EST

Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114

PTIXProtagenic Therapeutics2026-03-10 08:00 EST

Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market

PTIXProtagenic Therapeutics2025-12-09 08:46 EST

Results from Phase 1 Multiple-Dose Study of PT00114

Stock data

Close
0.73 USD
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States